International Society of Cutaneous Lymphoma (ISCL) and the European Organization of Research and Treatment of Cancer (EORTC) revisions to the staging and classification of mycosis fungoides and SÈzary syndrome.

Abstract

Madeleine Duvic, MD, is Professor of Internal Medicine and Dermatology, and Deputy Chairman of the Department of Dermatology at The University of Texas, M. D. Anderson Cancer Center in Houston, Texas. She is a founding member of the United States Cutaneous Lymphoma Consortium (USCLC), a Board member of the International Society for Cutaneous Lymphoma, and also serves as Director of The Cutaneous Lymphoma Clinic at MD Anderson Cancer Center. Dr. Duvic has also served on the Board of Directors of the American Academy of Dermatology (AAD). She is certified in Internal Medicine and Dermatology. She has been a principal and co-principal investigator on numerous clinical trials studying the immunology of T-cell mediated disorders and skin cancers, as well as clinical drug development and translational research in T-cell lymphomas, melanoma, and various skin cancers. A prolific author, she has written manuscripts, book chapters, abstracts, and over 300 peer-reviewed journal articles. She is co-author on a recent book on Retinoids and Carotenoids in Dermatology. Dr. Olsen is Professor of Dermatology and Oncology at Duke University Medical Center and the founder and Director of the Duke Cutaneous Lymphoma Research and Treatment Center. She is a Past President, SecretaryTreasurer and member of the Board of Directors of the International Society for Cutaneous Lymphomas (ISCL) and has chaired the ISCL initiatives on the revisions to 1) the staging and classification of Mycosis Fungoides (MF) and Sezary Syndrome (SS) (published in Blood 2007) and 2) standardized response criteria and endpoints for MF and SS (in progress). She is a founder and current President of the United States Consortium for Cutaneous Lymphomas (USCCL), a multidisciplinary group whose mission is to enhance patient care through a national registry of patients with cutaneous lymphoma and collaborative clinical trials. She has authored over 90 original articles and is the editor of two textbooks. Dr. Olsen is currently on the Board of Directors of the American Academy of Dermatology (AAD) and Deputy Chair of the AAD Patient Advocacy Task Force. As background to the following educational activity, this brief review will discuss the International Society of Cutaneous Lymphoma (ISCL) and the European Organization of Research and Treatment of Cancer (EORTC) revisions to the staging and classification of mycosis fungoides and Sezary syndrome.